mrrse

Migraine Drugs Market Estimated to Reach a US$ 3.72 Billion Value by 2025

May 6th 2019 at 4:40 AM

The expanding database of Market Research Reports Search Engine (MRRSE) has been recently updated by the addition of a new study which is titled as “Migraine Drugs Market Estimated to Reach a US$ 3.72 Billion Value by 2025”. The fact-based research report on the global Migraine Drugs market covers various aspects such as trends, drivers, challenges and opportunities that have an influence on the growth and expansion of the global market. All these factors are analyzed across key regions of Latin America, North America, Europe, Middle and Africa (MEA) and the Asia Pacific. In order to provide an accurate forecast, analysts have presented the current market, which forms the basis of how the metal caps and closures market is expected to develop in the future.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global migraine drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

The global migraine drugs market reached a value of US$2.72 bn in 2016 and is expected to reach a value of  US$3.72 bn by 2025. The global migraine drugs market is expected to register a steady CAGR 3.50% between 2017 and 2025.  The market is mainly segmented into three segments namely Treatment, Route of Administration, and Distribution Channel.

Request Free Sample Report @ https://www.mrrse.com/sample/3692

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global migraine drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different types of treatments & drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of migraine drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Migraine is type of headache, estimated to affect 12 to 14.7% of population across the globe. According to international as well regional guidelines it is categorized by frequency and nature of attack into episodic migraine and chronic migraine. Abortive and prophylactic are the two treatments offered for migraine relief. Abortive treatment which is given to abort acute attack of migraine include medication such as triptans, ergot alkoids and others. While prophylactic treatment is recommended to patients with chronic migraine to prevent migraine attacks using medications such as botulinum toxin, topiramate and other drugs.

Based on treatment, the global migraine drugs market has been segmented into abortive and prophylactic. These treatments segments are further classified based on the drug class such as abortive treatment is classified into triptans, ergot alkoids, and others while prophylactic treatment is segmented into botulinum toxin, topiramate and others. Abortive treatment segment is projected to hold dominant share of global migraine drugs market while prophylactic treatment segment is likely to register steady growth during the forecast period from 2017 to 2025.

Based on route of administration, the global migraine drugs market is segmented into oral, injectable and others. Others segment of route of administration include nasal sprays, transdermal patches, etc. Low cost and vast availability of orally administrable drugs is projected to contribute for dominating share of oral segment of route of administration.

Based on the distribution channel, the global migraine drugs market is segmented into retail pharmacies, hospital pharmacies and others. Ever increasing number of retail pharmacies, self-medication with widely available OTC migraine abortive drugs is attributed for the significant share of the segment in the global market.

Browse Complete Report with TOC @ https://www.mrrse.com/migraine-drugs-market

Geographically, the global migraine drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the migraine drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca Plc., Allergan Plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Eli Lilly & Co. Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceuticals Inc., Zosano Pharma Corporation, Alder BioPharmaceuticals Inc., and others.

The global migraine drugs market has been segmented as below:

Global Migraine Drugs Market, by Treatment

Abortive

Triptans

Ergot Alkaloids

Others

Prophylactic

Botulinum Toxin

Topiramate

Others

Global Migraine Drugs Market, by Route of Administration

Oral

Injectable

Others (Nasal Spray, Transdermal Patch, etc.)

Global Migraine Drugs Market, by Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Others (Online Pharmacies, Drug Stores, etc.)

Global Migraine Drugs Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

U.K.

Spain

Italy

Rest of Europe

Asia Pacific

India

China

Japan

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Israel

Rest of Middle East and Africa

Enquire about this Report @ https://www.mrrse.com/enquiry/3692

About Market Research Reports Search Engine (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com

0 comments
Please to comment

sign in

Username
Password
Remember Me


New to IM faceplate? join free!

Lost Password? click here